| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6487867 | Current Opinion in Biotechnology | 2014 | 8 Pages |
Abstract
- Marketed and clinical-stage yeast-derived biopharmaceuticals are commonplace.
- Engineering of N-glycosylation and O-glycosylation is revolutionizing yeast-based expression.
- Yeast provides a powerful tool for lead identification of novel biopharmaceuticals.
- Glycoengineered yeast provides an end-to-end platform for protein therapeutics.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Michael A Meehl, Terrance A Stadheim,